Haemonetics Corporation
400 Wood Road
Braintree
Massachusetts
02184
United States
Tel: 781-848-7100
Fax: 781-848-5106
Website: http://www.haemonetics.com/
Email: info@haemonetics.com
329 articles about Haemonetics Corporation
-
Haemonetics Announces Definitive Agreement to Acquire Attune Medical
3/5/2024
Haemonetics Corporation announced that it has entered into a definitive agreement to acquire privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures.
-
Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day
2/21/2024
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 8:45 a.m. ET.
-
Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference
2/21/2024
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5, 2024 at 7:30 a.m. ET.
-
Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
2/8/2024
Haemonetics Corporation announced that financial results for its third quarter fiscal year 2024, which ended December 30, 2023, are available on its Investor Relations website.
-
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024
1/11/2024
Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, February 8, 2024.
-
Haemonetics Corporation Completes Acquisition of OpSens Inc.
12/12/2023
Haemonetics Corporation has completed its previously announced acquisition of OpSens Inc.
-
Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
12/7/2023
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 9:45am Pacific time.
-
Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
11/2/2023
Haemonetics Corporation announced that financial results for its second quarter fiscal year 2024, which ended September 30, 2023, are available on its Investor Relations website.
-
Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.
10/10/2023
Haemonetics Corporation and OpSens, Inc. announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate.
-
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2024 Results: November 2, 2023
10/5/2023
Haemonetics Corporation announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, November 2, 2023.
-
Haemonetics Announces European Expansion for VASCADE® Vascular Closure System
8/29/2023
Haemonetics Corporation has announced that for the first time, patients have been treated with the company`s VASCADE MVP® Venous Vascular Closure system in Germany.
-
Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
8/8/2023
Haemonetics Corporation announced that financial results for its first quarter fiscal 2024, which ended July 1, 2023, are available on its Investor Relations website.
-
Diane M. Bryant Joins Haemonetics' Board of Directors
8/7/2023
Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has announced the election of Diane M. Bryant to its Board of Directors.
-
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2024 Results: August 8, 2023
7/10/2023
Haemonetics Corporation announced that the Company intends to publish first quarter fiscal year 2024 financial results at 6:00 am ET on Tuesday, August 8, 2023.
-
Haemonetics Receives FDA Clearance for Enhancements to NexSys PCS® Plasma Collection System
6/22/2023
Haemonetics Corporation, a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, announced it has received clearance from the U.S. Food and Drug Administration for advancements to its NexSys PCS® plasma collection system.
-
Haemonetics 4th Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
5/11/2023
Haemonetics Corporation announced that financial results for its fourth quarter fiscal 2023, which ended April 1, 2023, are available on its Investor Relations website.
-
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2023 Results: May 11, 2023
4/25/2023
Haemonetics Corporation announced that the Company intends to publish fourth quarter and fiscal year 2023 financial results at 6:00 am ET on Thursday, May 11, 2023.
-
Haemonetics Publishes Inaugural Corporate Responsibility Report
4/20/2023
Haemonetics Corporation today announced the release of its 2022 Corporate Responsibility Report.
-
Haemonetics Introduces Next Generation Intelligent Control Software for Cell Saver® Elite®+ Autotransfusion System
3/2/2023
Haemonetics Corporation has announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on the next-generation software for the Cell Saver ® Elite ® + Autotransfusion System.
-
Haemonetics to Present at Raymond James 44th Annual Institutional Investors Conference
2/27/2023
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 44th Annual Institutional Investors Conference on Monday, March 6, 2023, at 8:40 a.m. ET.